Lipidated Protein Production With Consistent E. coli Lipidation Profiles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing lipidated proteins face challenges in upscaling production while maintaining consistent lipid profiles, which affects the biological activity of the proteins, particularly for vaccines like Borrelia Outer surface protein A (OspA), SARS-CoV-2 Spike protein, and Clostridium difficile toxin proteins.
Innovation Solution
A method for producing lipidated proteins involves culturing E. coli cells in controlled conditions, including specific pH and headspace pressure, with optional trace element and antifoaming agent adjustments, to achieve consistent lipidation profiles, characterized by defined peak distributions in RP-HPLC analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If native chemical ligation is used to produce lipidated proteins, then full-length protein with correct post-translational modifications can be obtained, but the process requires multiple separate reactions and purification steps increasing complexity and time
Solution Approach 1:
The patent combines multiple ligation steps and purification operations into a single integrated one-pot reaction system. The thioester-containing protein, lipidated peptide, and ligation reagents are all present simultaneously in the same reaction vessel, allowing sequential ligation events to occur without intermediate purification, thereby reducing process complexity while maintaining modification accuracy
Solution Approach 2:
The patent prepares the thioester-containing protein and lipidated peptide with pre-installed specific functional groups (thioester group and N-terminal cysteine) that are designed to undergo automated ligation. This preliminary preparation enables the automated system to perform the ligation reactions directly without requiring manual intervention for each step
2Productivity
If native chemical ligation with automated ligation reagents is used, then full-length lipidated protein can be produced, but the process requires significant optimization and is time-consuming
Solution Approach 1:
The patent employs an automated ligation system where the ligation reagents and reaction conditions are pre-configured to perform the ligation reactions autonomously. The system automatically monitors and completes the ligation steps without requiring continuous manual optimization or intervention, significantly reducing the time and expertise needed compared to traditional manual methods
Solution Approach 2:
The patent optimizes and fixes key reaction parameters (such as reagent concentrations, pH, temperature, and reaction time) to establish a standardized protocol. By determining and locking these parameters in advance, the system eliminates the need for time-consuming optimization during each production run, enabling consistent and efficient full-length protein production
3Quantity of substance
If traditional methods are used to produce isotopically enriched amino acids, then amino acids can be obtained, but the process is complex and results in significant loss of material
Solution Approach 1:
The patent extracts and isolates the isotopically enriched amino acids from the complex reaction mixture after the ligation and expression processes. By using targeted purification methods to extract only the desired amino acids, the system minimizes material loss compared to traditional bulk processing methods that would require larger starting quantities and result in significant waste
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures consistent lipidation profiles, maintaining the biological activity of lipidated proteins, enabling large-scale production suitable for commercial use as vaccines.
Implementation Method 1
The method employs a thioester-containing protein and a lipidated peptide and performs a native chemical ligation between the two
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.G5) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C- TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).